Dr. Barcenas on Colestipol in Management of Neratinib Side Effects in HER2+ Breast Cancer

Carlos H. Barcenas, MD
Published: Tuesday, Feb 14, 2017



Carlos Barcenas, MD, assistant professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses managing neratinib-related side effects with colestipol (Colestid).

In an effort to keep patients on neratinib for an entire year, Barcenas is currently evaluating agents to see which will successfully treat the common side effect of diarrhea.

Colestipol, a bile acid sequestrant, has shown promise in managing diarrhea in patients with metastatic HER2-positive breast cancer who are on neratinib.
 


Carlos Barcenas, MD, assistant professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses managing neratinib-related side effects with colestipol (Colestid).

In an effort to keep patients on neratinib for an entire year, Barcenas is currently evaluating agents to see which will successfully treat the common side effect of diarrhea.

Colestipol, a bile acid sequestrant, has shown promise in managing diarrhea in patients with metastatic HER2-positive breast cancer who are on neratinib.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x